Mills A, Schulman K, Fusco J, et al. Validation of a chronic kidney disease risk score in HIV+ Patients in the U.S. [730]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 04-07 MAR 2018, 2018; Boston, MA
Research Category: Abstracts and Posters
Virologic Response To 2-Drug ART Regimens Among Treatment-Experienced HIV+ Patients
Pierone G, Henegar C, Fusco J, et al. Virologic Response To 2-Drug ART Regimens Among Treatment-Experienced HIV+ Patients. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2018; Boston, MA USA
The impact of HIV coinfection on hepatitis C virus (HCV) treatment initiation
Henegar C, Beckerman R, Fusco J. The impact of HIV coinfection on hepatitis C virus (HCV) treatment initiation. Presented at: International Conference on Pharmacoepidemiology 2017; Montreal, Canada
Uptake of HLA-B*5701 screening and its impact on clinically suspected hypersensitivity reaction to abacavir in the OPERA observational database
Mounzer K, Hsu R, Henegar C, et al. Uptake of HLA-B*5701 screening and its impact on clinically suspected hypersensitivity reaction to abacavir in the OPERA observational database [A-854-0101-0466]. Presented at: 9th IAS Conference on HIV Science 2017; Paris, France
Initial regimen duration in female patients taking integrase strand transfer inhibitors (INSTI) in the OPERA observational database
Carpio F, Henegar C, Fusco J, et al. Initial regimen duration in female patients taking integrase strand transfer inhibitors (INSTI) in the OPERA observational database [A-854-0129-02932]. Presented at: 9th IAS Conference on HIV Science 2017; Paris, France
Psychiatric disorders observed in HIV+ patients using 6 common 3rd agents in OPERA
Hsu R, Fusco J, Henegar C, et al. Psychiatric disorders observed in HIV+ patients using 6 common 3rd agents in OPERA [664]. Presented at: Conference on Retroviruses and Opportunistic Infections 2017; Seattle, WA, USA
Hepatitis C virus testing, prevalence, and treatment in a large cohort of treatment-naïve, HIV-positive individuals
Dieterich D, Henegar C, Fusco J, Lackey P. Hepatitis C virus testing, prevalence, and treatment in a large cohort of treatment-naïve, HIV-positive individuals. Presented at: AASLD The Liver Meeting 2016; Boston, MA, USA
Syphilis, race, baseline labs, and antiretroviral regimen predict virologic success in naïve HIV+ adolescents and young adults
Melikian G, Lackey P, Henegar C, Zelt S, Fusco J, Schulman K, D’Amico R, Wohlfeiler M. Syphilis, race, baseline labs, and antiretroviral regimen predict virologic success in naïve HIV+ adolescents and young adults [1512]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA
The impact of antiretroviral tablet burden and polypharmacy on viral suppression in treatment-naïve patients
Mills A, Fusco J, Schulman KL, et al. The impact of antiretroviral tablet burden and polypharmacy on viral suppression in treatment-naïve patients [1512]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA
Variability in population characteristics among HIV+ ART-naïve patients initiating on single tablet regimens
Melikian G, Fusco J, Schulman K, et al. Variability in population characteristics among HIV+ ART-naïve patients initiating on single tablet regimens [1517]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA